Roche on Gazyva in lupus nephritis presented at ASN/ACR 2019

Agenda:

Welcome

Roche in immunology – overview

Phase II Nobility data - efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with Lupus Nephritis

Q&A

Karl Mahler, Head of Investor Relations

Mark Eisner, Global Head of Product Development – Immunology, Infectious Disease & Ophthalmology

Larry Tsai, Global Head of Rheumatology & Respiratory Development

Please register to access the replay*

First Name

Last name

Corporate Email

Company Name

Confirm you are a human *

Roche has hosted a live audio webcast and conference call on Tuesday, 12 November 2019.

Investors

Downloads

PDF